Mackenzie Financial
PTGX icon

Mackenzie Financial’s Protagonist Therapeutics PTGX Stock Holding History

Mackenzie Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$453K Buy
+3,217
New +$458K ﹤0.01% 1334
2026
Q1 		– Sell
-3,648
Closed -$318K – 1689
2025
Q4 		$318K Sell
3,648
-416
-10% -$34K ﹤0.01% 1364
2025
Q3 		$270K Sell
4,064
-18,393
-82% -$1.05M ﹤0.01% 1459
2025
Q2 		$1.24M Sell
22,457
-241
-1% -$11.6K ﹤0.01% 957
2025
Q1 		$1.1M Buy
22,698
+1,349
+6% +$56.5K ﹤0.01% 953
2024
Q4 		$824K Buy
21,349
+13,575
+175% +$592K ﹤0.01% 993
2024
Q3 		$350K Buy
+7,774
New +$314K ﹤0.01% 1126
2023
Q3 		– Sell
-12,745
Closed -$284K – 1568
2023
Q2 		$284K Sell
12,745
-14,759
-54% -$369K ﹤0.01% 1184
2023
Q1 		$633K Buy
+27,504
New +$462K ﹤0.01% 958

Other funds holding PTGX

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Mackenzie Financial's PTGX Position: Q3 2026 in Review

Mackenzie Financial opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 3,217 shares worth $453K. The stake represents ﹤0.01% of the portfolio and ranks #1334 among its holdings. This is a return to the name: Mackenzie Financial previously reported a position in PTGX as recently as Q4 2025.

Mackenzie Financial first reported a position in PTGX in Q1 2023 and has held it in 9 quarters since. The position peaked at $1.24M in Q2 2025. 198 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Mackenzie Financial held 3,217 shares of Protagonist Therapeutics worth $453K as of Q3 2026.
  • Protagonist Therapeutics was a new Mackenzie Financial position in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Mackenzie Financial's portfolio in Q3 2026, its #1334 holding.
  • Mackenzie Financial first reported a position in Protagonist Therapeutics in Q1 2023 and has held it in 9 quarters since.
  • Mackenzie Financial's Protagonist Therapeutics position peaked at $1.24M in Q2 2025.
  • 198 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Mackenzie Financial's 13F filing for Q3 2026, filed 2 Nov 2026.